Despite the fact that it has been three years since the drug was approved by the FDA, many oncologists still need to be educated regarding Xofigo's benefits beyond pain palliation, The ...

Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has received marketing authorisation from the European Commission for Xofigo ® (radium Ra 223 dichloride) solution ...

Add Yahoo as a preferred source to see more of our stories on Google. Xofigo and Xtandi as a combination therapy in mCRPC has demonstrated a significant OS benefit over Xtandi alone in an investigator ...

Bayer thought it might be able to expand Xofigo in prostate cancer by testing it with Johnson & Johnson’s Zytiga. But that plan has hit a snag. The German drugmaker unblinded a phase 3 study combining ...

Bayer expects to launch the drug within the next few weeks. We note that Xofigo will be co-promoted by Bayer and Algeta US, LLC in the US. We remind investors that the FDA granted priority review to ...

PEACE-3 randomized 446 asymptomatic/mildly symptomatic mCRPC patients with bone metastases to enzalutamide ± radium-223, stratified by prior docetaxel, abiraterone, pain, and bone-targeting agents.

New data from the Phase III PEACE III trial showed that XOFIGO ® (radium-223 dichloride) in combination with enzalutamide significantly improved prostate-specific antigen (PSA) response rates (≥90% at ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

A different approach Bayer hopes Xofigo's more favorable dosing schedule can overcome patient fear over injections and higher prices to win business away from Johnson's oral Zytiga, which is dosed ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Xofigo" drug pipelines has been added to ResearchAndMarkets.com's offering. Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly ...